Genmab — Marts 2021
-
Ja: Robust development programmes are ongoing for mosunetuzumab and glofitamab, investigating the treatments as monotherapies and in combination with other molecules, as well as more convenient forms of administration such as subcutaneous administration, with several phase III trials planned in the near future.https://www.roche.com/media/releases/med-cor-2020-12-08.htm
-
We always need human trials. But its to closly related molecules, so there is a lot that can be compared in preclinical models vs dara clinical data
-
two closely....
-
14:13 @Bulder: men referencen til subcu kan jo være relateret til Mosunetuzumab, hvor vi har vist siden sidste efterår at Roche vil udvikle en subcu version
-
New smal trial - An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus (DARALUP) https://clinicaltrials.gov/ct2/show/NCT04810754?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHexabody&lupd_s=03%2F23%2F2021&draw=2&rank=1
-
Q&A starter kl. 15,30.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind